Collaborative Effort to Enhance NGS Technology, Advancing Precision Diagnostics for Rare Diseases and Cancer in APAC
Taipei, Taiwan – October 30, 2024
Advanced Genomics APAC recently announced a strategic alliance with Compass Bioinformatics Inc., focused on expanding the applications of next-generation sequencing (NGS) technology in the fields of rare disease and cancer diagnostics. This partnership will target market growth in Japan, South Korea, Southeast Asia, and the Australasia region, accelerating access to precision medicine for a wider audience.
In the realm of rare disease diagnostics, whole-exome sequencing (WES) stands as a foundational approach for pinpointing hereditary disorders. Leveraging Advanced Genomics APAC’s specialized Cell3™ Target: Nexome Panel, optimized to capture pathogenic variants effectively, and combined with Compass Bioinformatics’ advanced InheriNext® analytical software, this collaboration offers an end-to-end, streamlined diagnostic solution—from library preparation through to high-precision data interpretation—supporting medical teams in achieving faster, more accurate diagnoses.
Since its introduction in 2020, Compass Bioinformatics’ InheriNext® platform has been instrumental in over 3,500 rare disease diagnoses, achieving regulatory accolades such as U.S. FDA Class I Medical Device clearance, Taiwan TFDA’s stringent QMS certification, and ISO 13485 quality standards. By uniting Advanced Genomics APAC’s robust Cell3™ Target: Nexome with the power of Compass Bioinformatics’ data analysis platform, this partnership aims to elevate diagnostic efficiency across healthcare institutions in the APAC region. For patients with rare diseases, who often face diagnostic delays exceeding six years and where over 80% of cases are genetic, this partnership promises to shorten diagnosis time significantly, delivering faster and more precise care.
Andy Chang, General Manager of Advanced Genomics APAC, remarked, “This partnership presents an opportunity to deepen Nexome’s integration within the APAC diagnostic landscape, especially in advancing rare disease and cancer diagnostics. We believe this will have far-reaching impacts on enhancing patient quality of life.”
Ping-Cheng Hsiung, General Manager of Compass Bioinformatics, added, “We are thrilled to collaborate with Advanced Genomics APAC. Our synergy in both technological advancement and market expansion will empower more healthcare providers to harness cutting-edge genomic diagnostics, boosting both accuracy and efficiency.”
In the months ahead, the two companies plan to roll out services and present the outcomes of this collaboration to healthcare professionals across the APAC region, furthering the advancement of rare disease and oncology diagnostics.
For more details, please refer to the EIN Presswire|Newsmatics release below:
https://www.kron4.com/business/press-releases/ein-presswire/755790350/advanced-genomics-apac-joins-forces-with-compass-bioinformatics-to-advance-rare-disease-and-cancer-diagnostics
(If you cannot access the above link, please enter the URL directly)
About Advanced Genomics APAC
Advanced Genomics APAC Co. Ltd. provides cutting-edge genetic testing solutions across the Asia-Pacific region. As a subsidiary of Advanced Genomics Limited (UK), the company focuses on innovation and excellence to meet the rising demand for genetic testing services, enhance early cancer detection, and strengthen the accuracy of cancer diagnostics through strategic partnerships and advanced technology.
About Nonacus
Nonacus, a subsidiary of Advanced Genomics Limited (UK), specializes in the development of advanced genetic analysis products. The company is committed to providing innovative solutions that enhance early detection and personalized treatment of various medical conditions, including the GALEAS Tumor product.
Contact Information
For media inquiries, please contact:
Advanced Genomics APAC Co. Ltd.
Phone: +886 32870503
Email: infoapac@nonacus.com
For More Information
For more information about our new products and services, visit our website at https://www.aglapac.com/
